Oncology Central

The evolution of high complexity companion testing for targeted and immuno-oncology


As this article goes to press in late 2016, the precision medicine community has amassed over 20 years of companion product development experience in the field of oncology. This article reflects on what we have achieved and learned along the way, how the companion paradigm is playing out in immuno-oncology and why we are likely to achieve much more in the next 10 years than we have in the previous two decades. Also considered here are some of the disruptive operational and business model changes we will see in the coming years as these new opportunities are realized.

To view restricted content, please:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.